259 completed, 73 terminated, 53 unknown, 49 recruiting. 498 Phase 2, 167 Phase 1, 48 Phase 3.
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | SCAI Therapeutics | 50 | 2026-11-01 | 2026-05-26 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-11-01 | 2026-11-05 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD) 1 % Bevemipretide, 2% Bevemipretide, Vehicle - Dry AMD, Age-Related Macular Degeneration (AMD) | Phase 2 / Phase 3 | Not yet recruiting | Mighty Therapeutics, Inc. | 300 | 2026-11-01 | 2026-11-09 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) RTx-015, Sham Control - Retinitis Pigmentosa (RP), Inherited Retinal Diseases | Phase 2 / Phase 3 | Recruiting | Ray Therapeutics, Inc. | 60 | 2026-10-01 | 2026-10-28 |
| A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration BRX011, Placebo - Geographic Atrophy | Phase 1 / Phase 2 | Recruiting | Biojiva LLC | 152 | 2026-09-29 | 2026-09-23 |
| A Study in Adults With Geographic Atrophy STL303, Placebo - Geographic Atrophy | Phase 2 | Recruiting | Sitala Bio LTD | 300 | 2026-09-11 | 2026-09-21 |
| An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy PST-611 - Geographic Atrophy, Age - Related Macular Degeneration (AMD) | Phase 2 | Not yet recruiting | Eyevensys | 24 | 2026-09-01 | 2026-07-16 |
| First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) BETA-TT8 ophthalmic gel 3.8% w/v - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Not yet recruiting | Filamon LTD | 24 | 2026-09-01 | 2026-09-18 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients 9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa | Phase 1 / Phase 2 | Enrolling by invitation | Sheba Medical Center | 41 | 2026-07-26 | 2026-07-27 |
| Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | Recruiting | AiViva BioPharma, Inc. | 35 | 2026-07-01 | 2026-11-04 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Phase 2 Study of NT-101 Topical in Patients With Wet AMD NT-101 ophthalmic solution, Placebo - Wet Age Related Macular Degeneration | Phase 2 | Recruiting | NexThera Co., Ltd. | 66 | 2026-06-11 | 2026-09-16 |
| Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration Ixo-vec - Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Phase 2 | Recruiting | Adverum Biotechnologies, Inc. | 15 | 2026-06-02 | 2026-08-05 |
| A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Theratocular Biotek Co. | 31 | 2026-06-02 | 2026-06-25 |
| Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD EG-301, AREDS2 supplements - Non-Exudative (Dry) Age-related Macular Degeneration (dAMD) | Phase 2 | Not yet recruiting | Evergreen Therapeutics, Inc. | 90 | 2026-06-01 | 2025-12-08 |
| Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration EYC-0305 - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Eyconis INC. | 30 | 2026-05-19 | 2026-10-09 |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
| Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM - Retinitis Pigmentosa | Phase 2 / Phase 3 | Not yet recruiting | PT. Prodia Stem Cell Indonesia | 30 | 2026-05-01 | 2026-02-25 |
| A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 12 | 2026-04-16 | 2026-04-17 |
Showing 20 of 498. Sign in to see all of them.
Macular Degeneration (267) · Macular Edema (100) · Retinitis Pigmentosa (71) · Geographic Atrophy (69) · Retinal Diseases (52) · Choroidal Neovascularization (43) · Eye Diseases (42) · Wet Macular Degeneration (29) · Diabetic Retinopathy (26) · Retinal Vein Occlusion (23) · Stargardt Disease (22) · Vision Disorders (17) · Diabetes Mellitus (15) · Eye Diseases, Hereditary (13)
Eye Diseases (456) · Retinal Diseases (446) · Macular Degeneration (146) · Eye Diseases, Hereditary (118) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (105) · Genetic Diseases, Inborn (101) · Pathological Conditions, Signs and Symptoms (88) · Retinal Dystrophies (71) · Uveal Diseases (62) · Pathologic Processes (53) · Metaplasia (51) · Choroid Diseases (49) · Cardiovascular Diseases (46) · Neovascularization, Pathologic (46)
Ranibizumab (89) · Bevacizumab (30) · salicylhydroxamic acid (30) · aflibercept (28) · Dexamethasone (18) · Verteporfin (11) · Triamcinolone Acetonide (9) · Calcium Dobesilate (8) · Sirolimus (7) · pegaptanib (7) · Intravitreal Injections (6) · Minocycline (6) · Acetazolamide (5) · Brimonidine Tartrate (5) · Fluocinolone Acetonide (5)
National Eye Institute (NEI) (18) · Allergan (16) · Alcon Research (8) · Genentech, Inc. (8) · Novartis Pharmaceuticals (8) · Johns Hopkins University (7) · Beacon Therapeutics (6) · Boehringer Ingelheim (6) · Santen Inc. (6) · University of Sao Paulo (6) · AbbVie (5) · GlaxoSmithKline (5) · Laboratoires Thea (5) · Sanofi (5) · Shahid Beheshti University of Medical Sciences (5)
United States (315) · United Kingdom (47) · Germany (40) · Australia (37) · France (34) · Canada (26) · Italy (25) · China (23) · Israel (21) · Spain (21) · Czechia (17) · Hungary (17) · Poland (17) · Brazil (15) · Austria (12)
Robert W Snyder, MD, PhD (4) · Timothy C Fagan, MD (4) · Anne Fung, MD (3) · Jennifer Henrick, RN, MS (3) · Joel Naor, MD (3) · Mohamed Genead, MD (3)
PMID 37314061, PMID 37702300, PMID 40547876, PMID 33331670, PMID 22281388, PMID 23049090, PMID 23668681, PMID 25458728, PMID 30194931, PMID 32134802, PMID 32573764, PMID 33206392, PMID 37140896, PMID 39207600, PMID 10511047, PMID 11931789, PMID 15079763, PMID 15302656, PMID 16759390, PMID 17342504, PMID 17353400, PMID 18321465, PMID 18441371, PMID 19268890, PMID 19376495, PMID 19748675, PMID 19878113, PMID 20189159, PMID 20212194, PMID 20212197, PMID 20574018, PMID 20609706, PMID 20688744, PMID 20847709, PMID 20926818, PMID 21087953, PMID 22424834, PMID 22828504, PMID 22927737, PMID 23316779, PMID 23361508, PMID 23548622, PMID 23795985, PMID 23828615, PMID 24053892, PMID 24289920, PMID 24354307, PMID 24408973, PMID 24439297, PMID 24705452
2017 (4), 2025 (4), 2009 (3), 2015 (3), 2016 (3), 2018 (2), 2019 (2), 2014 (1), R21EY033579 (1), U10EY014231 (1), U10EY018817 (1)